UNDERSTANDING CANCER · TESTS & INVESTIGATIONS
Cancer Aware / Tests & Investigations
Cancer Tests & Investigations — A Complete Patient Guide
Know why a test is needed, what it can tell you, and what happens next.
A practical reference for patients and caregivers—from the first abnormal result to treatment monitoring and follow-up. You do not need every test in this guide.
Medical Content & Review
Dr Hakeem Ansar Hussain
Medical Oncologist
Last medically reviewed:
Need a quick answer? Does biopsy spread cancer? · PET-CT · Grade versus stage · 35 FAQs · Urgent warning signs
Severe bleeding, breathlessness, a serious allergic reaction, new neurological symptoms or rapid deterioration? Seek urgent medical care. Do not wait for routine reports.
In this guide
Choose a topic, or read in order. Each heading has a stable link for sharing.
- 1. Understanding the diagnostic journey
- Can a blood test diagnose—or exclude—cancer?
- Can imaging alone confirm cancer?
- 2. Biopsy: the foundation of diagnosis
- Types of biopsy: what each sample can tell us
- Is biopsy painful? What is recovery like?
- Is biopsy dangerous?
- Does biopsy spread cancer? Myth versus fact
- Why might a biopsy be inconclusive or repeated?
- What happens to the sample?
- 3. Understanding your histopathology report
- Grade versus stage: different questions
- What are surgical margins?
- Lymphovascular and perineural invasion
- What does Ki-67 mean?
- Poor differentiation and second pathology opinions
- 4. What is IHC, and why are additional stains needed?
- Common IHC examples
- HER2 testing: scores need context
- PD-L1: TPS and CPS are not interchangeable
- MMR and MSI: related, but different tests
- 5. Radiology: choosing the right view
- Ultrasound, Doppler and X-ray
- CT and contrast-enhanced CT
- MRI: detailed soft-tissue assessment
- PET-CT: what the scan actually shows
- What do FDG uptake and SUV mean?
- Positive PET, negative PET: both have limitations
- PET-CT versus CT versus MRI
- PSMA PET-CT for selected prostate cancer settings
- Other specialised imaging
- 6. Blood tests: treatment safety as well as diagnosis
- CBC: haemoglobin, white cells, ANC and platelets
- Liver tests: bilirubin, AST, ALT, ALP and albumin
- Kidney function and electrolytes
- LDH, calcium and clotting tests
- 7. Tumour markers: useful only in the right setting
- PSA, CA-125, CEA, CA 19-9, AFP, beta-hCG and LDH
- Can normal markers exclude cancer? Does a rise mean failure?
- 8. Molecular testing and precision oncology
- What is next-generation sequencing (NGS)?
- Common molecular biomarkers: what the names mean
- Actionable alterations and variants of uncertain significance
- Tissue testing versus blood-based testing
- 9. Liquid biopsy: what is being sampled?
- ctDNA: what it can—and cannot—tell us
- Molecular residual disease (MRD)
- 10. Somatic versus germline: is it inherited?
- Germline testing, BRCA and Lynch syndrome
- Who may need counselling? What does a negative result mean?
- 11. Staging: mapping the extent of disease
- Clinical versus pathological stage
- Does stage IV always mean the same prognosis?
- 12. How do doctors know treatment is working?
- RECIST and the language of response
- Pseudoprogression during immunotherapy
- PET metabolic response and repeat scans
- 13. Preparing safely for tests
- Before a CT scan
- Before PET-CT
- Before MRI
- Before and after biopsy
- Imaging radiation, contrast reactions and kidney safety
- 14. Cancer test myths versus facts
- 15. Frequently asked questions
- 16. Questions to ask before a test
- Understanding and organising your reports
- An illustrative investigation timeline
- 17. When to seek urgent medical attention
- Continue learning
- 18. Medical sources and review status
1. Understanding the diagnostic journey
Waiting for investigations can be unsettling. Each test should answer a particular question: is there an abnormality, what is it, where is it, or which treatment is likely to help? An abnormal result is a clue, not always a diagnosis. Results are interpreted together with your symptoms, examination and previous records.
| Purpose | What it means | Example |
|---|---|---|
| Screening | Testing people without symptoms to find selected cancers or precancerous changes early. | Mammography or cervical screening in eligible people. |
| Diagnosis | Finding the cause of a symptom or abnormal screening result. | Sampling a suspicious breast lump. |
| Staging | Assessing the extent of a confirmed cancer. | Chest and abdominal imaging when indicated. |
| Biomarker testing | Characterising cancer to help classify it or choose treatment. | ER/HER2 testing in breast cancer. |
| Response assessment | Checking how disease changes during or after treatment. | Comparing a follow-up CT with a baseline scan. |
| Surveillance | Planned follow-up after treatment to look for recurrence and other health needs. | Selected examinations, scans or markers at appropriate intervals. |
The usual pathway is symptoms or screening → examination and initial tests → tissue or cell sampling → pathology classification → selected IHC or molecular tests → staging → multidisciplinary planning. These steps can overlap or occur in a different order. A multidisciplinary team brings together relevant cancer specialists.
No single test suits every patient. A costlier scan or larger gene panel is useful only if it can answer a relevant question. Whole-body PET-CT is not routine screening for healthy people. Read Cancer Screening and Understanding Your Cancer Diagnosis.
Sources: [1].
Can a blood test diagnose—or exclude—cancer?
Routine blood tests can reveal anaemia, abnormal blood cells or organ problems, but may remain normal in someone with a solid tumour. An abnormal CBC does not automatically mean cancer either. Selected blood cancers can be identified using blood-cell examination, flow cytometry (testing cell markers) and genetic tests; marrow sampling may also be needed.
Persistent concerning symptoms still deserve assessment even when a CBC or tumour marker is normal. Do not buy a “cancer blood-test package” as a substitute for clinical assessment or recommended screening.
Can imaging alone confirm cancer?
Scans show location, size and patterns that may strongly suggest cancer. Usually they cannot establish the exact cell type, and infection or benign disease can look similar. Biopsy is commonly needed before systemic treatment.
There are carefully defined exceptions. In an appropriate high-risk liver population, a characteristic pattern on dedicated multiphase CT or MRI can establish hepatocellular carcinoma without biopsy. Some suspicious operable masses may be removed first, with diagnosis made on the surgical specimen. If biopsy is unsafe or impractical, specialists may sometimes recommend treatment based on a sufficiently convincing clinical and imaging picture after multidisciplinary review. Ask what criteria apply and what uncertainty remains; these exceptions do not make ordinary scans a universal replacement for tissue.
Sources: [12].
2. Biopsy: the foundation of diagnosis
A biopsy takes cells or tissue from an abnormal area. A pathologist, a doctor who diagnoses disease from samples, studies the material and may request additional tests. Tissue can distinguish cancer from inflammation and identify the subtype needed to plan treatment. Cytology examines individual cells; histology examines tissue and its arrangement.
The team chooses a safe, informative site—not necessarily the largest lump—and considers whether enough material is needed for biomarkers. Imaging may be performed first to plan the procedure. Tell the team about bleeding problems, medicines, allergies, pregnancy and previous procedures.
Types of biopsy: what each sample can tell us
| Method | Sample and usual purpose | Important limitation |
|---|---|---|
| FNAC: fine-needle aspiration cytology | A thin needle collects cells or fluid; useful for selected lumps, lymph nodes and thyroid lesions. | Limited tissue architecture. Cell blocks may permit extra testing, but FNAC is not always enough for full classification. |
| Core needle biopsy | A needle removes small cylinders of tissue, often under local anaesthesia. | Preserves more architecture and usually supports IHC; adequate viable tissue is still required for molecular tests. |
| Incisional biopsy | An operation removes part of a lesion. | Needs careful planning, particularly for a possible sarcoma. |
| Excisional biopsy | The whole abnormal lump or lymph node is removed. | Provides more tissue and architecture; not automatically the best first step for every mass. |
| Endoscopic biopsy | Forceps or a needle take samples through a scope, such as during gastroscopy, colonoscopy or bronchoscopy. | Samples may be small or superficial; deeper disease may need another approach. |
| Image-guided biopsy | Ultrasound, CT or another imaging method directs a needle. | Describes guidance, not a separate tissue type; organ-specific risks remain. |
| Bone marrow aspiration and trephine | Aspiration collects liquid marrow for cells, flow and genetic tests; trephine takes a small solid core to assess architecture. | The two are complementary. A poor aspirate may require other samples or tests. |
| Surgical biopsy | Open or keyhole surgery obtains tissue when appropriate. | May need general anaesthesia and greater recovery time. Incisional and excisional biopsies are surgical methods. |
For suspected lymphoma, architecture and fresh material for specialised tests may matter. A planned core or excisional biopsy is often more informative than FNAC alone. For a suspected bone or soft-tissue sarcoma, consult the specialist team before biopsy or removal.
Is biopsy painful? What is recovery like?
Local anaesthetic usually causes a brief sting, then numbs the sampling area. You may still feel pressure. Some biopsies use sedation or general anaesthesia. During marrow aspiration there can be brief deep pulling pain despite local anaesthetic; tell the team if pain control is insufficient.
Mild soreness or bruising can follow. Recovery depends on the site and technique. Follow the written instructions for dressings, bathing, activity and pain relief. If sedated, arrange an escort and follow the centre’s driving restrictions. Severe or increasing symptoms are not something to simply endure.
Sources: [2].
Is biopsy dangerous?
Most planned biopsies are completed safely, but no procedure is risk-free. Possible complications include bleeding, infection, pain and injury to nearby structures. A lung biopsy may cause a collapsed lung (pneumothorax); an endoscopic procedure can rarely perforate an organ. Deep-organ biopsies may require observation for internal bleeding. Sedation and anaesthesia have their own risks.
Your risk depends on the organ, route, medicines, blood counts and general health. Ask which symptoms are expected and whom to contact after discharge. A small skin puncture does not mean internal complications are impossible.
Sources: [2].
Does biopsy spread cancer? Myth versus fact
Myth: “A biopsy opens up the cancer and makes it spread.”
Fact: Appropriately performed diagnostic biopsies do not ordinarily cause clinically meaningful spread. Avoiding a necessary biopsy can delay the correct diagnosis and treatment.
Needle-tract seeding—tumour cells growing along a biopsy path—is rare but recognised in selected settings. The risk is not zero. Biopsy route and technique therefore matter, particularly for certain sarcomas: the specialist plans a track that can be included in definitive surgery when appropriate. Some organs and tumour types require a specific diagnostic approach.
A cancer found to have spread after biopsy may already have had microscopic or previously undetected spread. The timing alone does not prove that the biopsy caused it. Discuss your specific procedure rather than delaying it because of this myth.
Why might a biopsy be inconclusive or repeated?
- Too few cells or too little tissue were obtained.
- The sample contained mainly necrosis (dead tissue) or missed the abnormal area.
- The appearance is uncertain or does not fit the scan or clinical findings.
- Additional tissue is needed for IHC or predictive biomarkers.
- A new lesion could be a different cancer or a non-cancer condition.
- Progression raises a question of acquired resistance or transformation into a different subtype.
“No malignancy seen” describes the submitted sample. It does not always exclude cancer elsewhere in the lesion. If the findings do not match, the team may review the slides, target another area or recommend another sampling method. A repeat test is not automatically evidence of an earlier error.
What happens to the sample?
The laboratory checks identification, preserves and processes the sample, cuts thin sections and applies stains. A pathologist examines its shape and structure. Additional stains, IHC, flow cytometry, chromosome studies or molecular testing are requested when needed. Some investigations need fresh material and must be planned before collection.
Turnaround varies with tissue processing, bone decalcification, specialist review and tests sent to other laboratories. There is no universal number of days. Ask when the preliminary report and any addendum are expected, who will explain them and what to do if they are delayed. A pending test does not itself mean a worse diagnosis.
3. Understanding your histopathology report
| Term | Patient-friendly meaning |
|---|---|
| Histological diagnosis and tumour type | The name and category of disease, such as adenocarcinoma or lymphoma. |
| Grade and differentiation | How abnormal the cells and tissue pattern appear, using a cancer-specific system. |
| Tumour size | The measured size in the submitted specimen; a small biopsy cannot always establish the total size. |
| Margins | Whether tumour reaches a cut edge of surgically removed tissue. |
| Lymphovascular invasion (LVI) | Tumour cells seen within small lymphatic or blood-vessel spaces. |
| Perineural invasion (PNI) | Tumour cells involving or tracking along nerves. |
| Lymph nodes | How many were examined and how many contained tumour, with additional details when relevant. |
| Extranodal extension | Tumour extends beyond the lymph-node capsule into surrounding tissue. |
| Treatment effect | Changes after therapy, sometimes with an estimate of residual viable tumour or a response score. |
Not every field belongs in every report. A needle biopsy and a resection specimen answer different questions. “Pending IHC” means the classification may need further information; an addendum can complete the report. Ask your oncologist to explain the final integrated diagnosis.
Sources: [4].
Grade versus stage: different questions
| Grade | Stage |
|---|---|
| How abnormal or aggressive tumour cells look microscopically. | How extensive the cancer is, usually anatomically. |
| Systems vary: some use grades 1–3; others have different groups or scores. | Many solid tumours use TNM and stage groups, but blood and brain cancers may use other systems. |
| A high-grade tumour can still be localised. | A low-grade tumour can sometimes be widespread. |
Stage groups in some cancers also incorporate biological factors. Grade, stage and biomarkers together help guide treatment; none should be interpreted in isolation.
What are surgical margins?
A negative or clear margin means tumour is not seen at the assessed cut edge. A positive or involved margin means tumour reaches the relevant edge. A close margin means the distance is small, but “close” has no single definition for every cancer or operation.
The significance depends on the site, specimen orientation, invasive versus in-situ disease and planned radiotherapy or other treatment. A positive margin may prompt more surgery or another treatment, but it is not automatically stage IV. Clear margins do not guarantee that recurrence is impossible.
Sources: [4].
Lymphovascular and perineural invasion
LVI means cells are seen within small vessels. It can indicate a higher recurrence risk in some cancers and influence postoperative treatment discussions. It does not itself prove that a distant organ contains metastases.
PNI means tumour involves nerves. In selected cancers it affects risk assessment, local treatment planning or prognosis. It is not the same as a brain metastasis. Both findings need interpretation alongside stage, margins and the tumour’s other features.
What does Ki-67 mean?
Ki-67 is a protein found in dividing cells. The reported percentage estimates the proportion of tumour cells staining for this proliferation marker in the assessed sample. It is used differently in different cancers—for example, in grading many well-differentiated neuroendocrine tumours and in selected breast or lymphoma assessments.
Sampling, the area counted, laboratory methods and tumour type affect interpretation. A high Ki-67 does not automatically mean stage IV; a low value does not prove that cancer is harmless. It cannot by itself determine the best treatment. Ask what the value changes for your particular diagnosis.
Sources: [17].
Poor differentiation and second pathology opinions
Well-differentiated cells retain more resemblance to their original tissue; poorly differentiated cells resemble it less. This can indicate more aggressive biology, but behaviour also depends on subtype, extent, molecular features and treatment sensitivity. “Undifferentiated” disease may require additional tests to establish its origin.
Expert review is particularly useful for rare cancers, sarcomas, lymphomas, borderline diagnoses or findings that do not fit the clinical picture. The receiving laboratory may request original slides, paraffin blocks, reports and imaging details. Preserve access to these materials and ask how they will be returned.
4. What is IHC, and why are additional stains needed?
Immunohistochemistry (IHC) uses antibodies as laboratory probes to show particular proteins in tissue. A pattern of stains helps the pathologist identify the cell lineage, classify a lymphoma or other tumour, suggest a likely primary site and assess treatment-related biomarkers.
A “positive” stain means staining was detected according to that test’s criteria—not necessarily that cancer has been proved. A “negative” result means expected staining was not demonstrated; sample quality and controls matter. The pathologist integrates cell appearance, stain location, intensity, extent, control tissue and the complete panel. One marker rarely tells the whole story.
IHC is not the same as NGS: IHC generally examines proteins, while sequencing examines DNA or RNA. They can be complementary, and some findings need confirmation with a different method.
Sources: [18].
Common IHC examples
| Cancer context | Markers and what they help assess |
|---|---|
| Breast | ER and PR assess hormone receptors; HER2 helps classify a treatment-relevant protein pattern. |
| Lung | TTF-1 and p40 help classify selected lung carcinomas; PD-L1 and selected other predictive tests help treatment planning. |
| Colorectal | MMR proteins assess the mismatch-repair pathway. |
| Lymphoma | CD20 and CD3 help assess B-cell and T-cell lineage within a larger panel. |
| Neuroendocrine tumours | Synaptophysin, chromogranin and INSM1 support neuroendocrine differentiation with morphology. |
| Prostate | PSA and NKX3.1 can support prostatic origin in an appropriate diagnostic setting. |
Expression can overlap between tumours or be absent in an expected site. For example, TTF-1 positivity alone is not absolute proof of a lung primary. Staining PSA in tissue is a different use from measuring PSA in blood.
Sources: [18].
HER2 testing: scores need context
HER2 is a growth-related protein encoded by ERBB2. In breast cancer, IHC is commonly reported as 0, 1+, 2+ or 3+. An equivocal 2+ result usually needs in-situ hybridisation (ISH), which assesses gene copies, to establish conventional HER2 status. A 3+ result generally indicates HER2 positivity under the relevant criteria.
Lower expression can also matter for eligibility for particular antibody–drug conjugates in selected settings. An IHC 0 result can contain nuances relevant to some indications. Scoring, eligible treatments and thresholds differ across breast, stomach and other cancers; do not transfer a breast interpretation to every tumour. HER2 protein expression, gene amplification and a HER2 mutation are related but distinct findings. The report, cancer type, treatment history and locally applicable drug indication must all be checked.
PD-L1: TPS and CPS are not interchangeable
PD-L1 is a protein involved in controlling immune responses. Tissue staining can help select immunotherapy in some cancers and settings. TPS, or tumour proportion score, is the percentage of viable tumour cells with qualifying membrane staining. CPS, or combined positive score, includes qualifying stained tumour cells and certain immune cells, divided by the number of viable tumour cells and multiplied by 100, capped at 100.
Different assays, scoring systems and cut-offs are validated for different uses. The same number reported as TPS and CPS does not mean the same thing. PD-L1 is not a universal predictor: some positive tumours do not respond, and some negative tumours can benefit from an indicated immunotherapy regimen. Ask which assay and score apply to your treatment decision.
MMR and MSI: related, but different tests
Mismatch repair (MMR) is a DNA error-correction system. IHC commonly checks four proteins: MLH1, PMS2, MSH2 and MSH6. Loss of the expected expression pattern with valid controls can indicate deficient repair (dMMR); retained expression is described as proficient repair (pMMR).
Microsatellite instability (MSI) tests examine changes in repeated DNA sequences, using a validated molecular method. MSI-H means high instability; MSS means microsatellite stable. dMMR often corresponds to MSI-H, but the tests are not identical and discordant or unusual findings may need review.
These results can affect selected immunotherapy decisions and prompt Lynch syndrome assessment. They do not by themselves prove an inherited syndrome: tumour-specific causes also occur. Additional tumour tests and germline counselling/testing depend on the cancer and protein-loss pattern.
Sources: [23].
5. Radiology: choosing the right view
Imaging can locate a lesion, guide a biopsy, assess spread and compare response. A radiologist interprets structural scans; nuclear medicine specialists interpret tracer imaging. The request should include the clinical question and relevant treatment dates. Bring previous actual images as well as reports, because comparison is often essential.
“Indeterminate” means the finding cannot yet be confidently classified. The next step might be comparison, a different scan, follow-up or biopsy—not automatically a cancer diagnosis.
Sources: [1].
Ultrasound, Doppler and X-ray
Ultrasound uses sound waves, with a probe moved over gel on the skin or, for selected studies, placed in a body cavity. It can assess organs, fluid and superficial lumps and guide a needle. Doppler examines blood flow. It has no ionising radiation, but gas, bone, depth and operator factors can limit what is visible.
X-ray uses ionising radiation to give a projection image, often of the chest or bones. It is quick and useful for specific questions, but overlapping structures and limited detail can hide disease. A normal chest X-ray does not exclude every lung cancer. Further imaging depends on symptoms and the clinical question.
CT and contrast-enhanced CT
Computed tomography (CT) combines X-ray images into cross-sectional views. You lie on a moving table and may be asked to hold your breath briefly. CT is commonly used to assess the chest, abdomen and pelvis, look for spread and measure lesions over time.
Contrast-enhanced CT (CECT) may use an iodine-containing injection to distinguish vessels and tissues; oral contrast is used for selected examinations. An unenhanced scan is appropriate for some questions but does not always answer what a contrast study can. CT uses radiation, so the region and protocol should be justified.
Tell the centre about prior contrast reactions, kidney disease, recent acute illness, medicines and possible pregnancy. Kidney function is assessed when indicated. Serious allergic-like reactions are uncommon but possible; an alternative test or tailored precautions may be needed. A brief warm sensation with contrast is not necessarily an allergy.
MRI: detailed soft-tissue assessment
Magnetic resonance imaging (MRI) uses a powerful magnet and radio waves, not ionising radiation. It is particularly useful for the brain, spinal cord, pelvic structures, liver and prostate. During the scan you lie still in a noisy scanner; hearing protection is supplied, and some sequences require breath-holding.
Gadolinium contrast is used when it adds useful information. Tell the team about kidney disease: agent choice and necessity matter, particularly with severe impairment. Trace retention can occur after gadolinium; this is another reason to use it when clinically justified.
Report pacemakers, clips, implants, metal fragments and any device before entering the MRI area. Some devices are MRI-conditional and can be scanned only under specified conditions. Bring the device card. Discuss claustrophobia early so the centre can plan support or sedation if needed.
PET-CT: what the scan actually shows
PET means positron emission tomography. A small amount of a radioactive tracer is injected, and the scanner detects its distribution. CT locates the tracer activity anatomically. The CT component may be low-dose for localisation or a separate diagnostic-quality scan; do not assume every PET-CT includes a full contrast CT.
The common tracer FDG is a glucose-like substance. Many cancers use it avidly, but active immune cells and normal organs also take it up. After injection there is an uptake period, followed by scanning while you lie still. The choice of tracer and timing depend on the cancer and question.
PET-CT can be valuable for staging or response assessment in selected cancers, including many lymphomas. It does not replace biopsy, detect every tumour or make other imaging unnecessary. For example, brain MRI may be needed even when PET-CT has been performed.
What do FDG uptake and SUV mean?
FDG uptake describes where the glucose-like tracer accumulates. SUV, or standardised uptake value, is a semiquantitative measure of tracer concentration adjusted for factors such as injected dose and body size. SUVmax describes the highest measured value in the assessed region.
SUV is not a cancer score and there is no universal number that separates cancer from infection. It is affected by blood glucose, uptake time, scanner technique, lesion size, body-size correction and treatment timing. Comparisons are most useful with consistent protocols and specialist interpretation. A higher SUV does not, by itself, establish stage or prognosis.
Sources: [28].
Positive PET, negative PET: both have limitations
- False-positive uptake: infection, inflammation, healing after surgery or radiotherapy, recent vaccination and other benign processes can look active. In India, tuberculosis is an important possible mimic in the right context.
- False-negative results: very small lesions, some slow-growing or low-FDG-avid cancers and technical factors can reduce detection.
- Normal physiological uptake in organs such as the brain, heart or urinary tract can obscure or complicate interpretation.
- High blood glucose and poorly timed studies can affect image quality or interpretation.
A positive PET does not always mean cancer, and a normal PET does not exclude it. An unexpected finding that would change treatment may need targeted imaging, follow-up or tissue confirmation. Tell the team about recent infection, vaccinations, surgery and cancer treatment.
PET-CT versus CT versus MRI
| Test | Typical strengths | Limitations and practical points |
|---|---|---|
| CT | Fast structural overview; lung detail; many staging and response assessments. | Radiation; contrast may be required; limited ability to identify exact histology. |
| MRI | Detailed soft tissue; brain, spine, liver, pelvis and prostate questions. | Longer examination; movement and claustrophobia; device screening; contrast sometimes needed. |
| PET-CT | Tracer activity plus location; selected staging and metabolic response questions. | Tracer-specific; false positives/negatives; radiation; cost; CT portion may not be a diagnostic CECT. |
Sometimes two scans are complementary. An additional scan is justified when it answers a question that could change care, not simply because it is described as “more advanced”.
PSMA PET-CT for selected prostate cancer settings
PSMA PET uses a tracer directed at prostate-specific membrane antigen rather than glucose metabolism. It can help stage selected higher-risk prostate cancers, investigate biochemical recurrence (such as a rising PSA after treatment), or assess eligibility for certain PSMA-directed treatments.
It is not a general cancer screening scan. Some prostate cancers show little PSMA expression, and uptake is not exclusive to prostate cancer. A negative scan at a low PSA does not prove absence of microscopic disease. Read the Prostate Cancer guide.
Sources: [29].
Other specialised imaging
- DOTATATE PET assesses somatostatin receptors, especially in selected well-differentiated neuroendocrine tumours; it can help assess suitability for receptor-targeted treatment. It is not interchangeable with FDG PET.
- A bone scan shows areas of bone turnover. Arthritis, healing fractures and other non-cancer processes may produce hot spots; some tumour patterns are less conspicuous.
- Mammography uses low-dose X-rays for breast screening or diagnostic assessment. Suspicious findings may need ultrasound, additional views or biopsy.
- Breast MRI is used for specific high-risk screening or diagnostic/staging questions; extra findings may still need sampling. It does not replace mammography for everyone.
- Whole-body MRI can be useful in selected settings, such as myeloma or certain inherited-risk programmes; it is not a routine test for everyone.
- Diffusion, perfusion and contrast-enhanced techniques provide additional functional or blood-flow information for defined questions.
Ask which tracer or protocol was ordered and why. A differently named scan may measure a different biological process, rather than simply being a better version of the same test.
6. Blood tests: treatment safety as well as diagnosis
A blood sample can provide several types of information. Reference ranges vary between laboratories, and trends may be more useful than a single flagged value. Bring the actual report, including units and date. Ask which abnormalities need action today and which can be followed.
Sources: [14].
CBC: haemoglobin, white cells, ANC and platelets
- Haemoglobin carries oxygen in red cells. A low value indicates anaemia; causes include bleeding, nutritional deficiency, kidney disease, marrow involvement or treatment.
- White blood cells help fight infection. An abnormal total count needs interpretation with the differential and sometimes a blood film.
- Neutrophils are infection-fighting white cells. The absolute neutrophil count (ANC) is their actual number, not just their percentage. Low ANC can increase infection risk.
- Platelets help stop bleeding. A low count can increase bleeding risk; a high count has several possible causes.
CBC is checked before many treatments because marrow suppression can affect safety, timing or dose. It does not measure all aspects of fitness and cannot rule out a solid tumour. Fever or sudden illness during treatment needs prompt contact even if a recent CBC was acceptable.
Liver tests: bilirubin, AST, ALT, ALP and albumin
Bilirubin reflects processing and drainage of bile pigments; a rise may accompany jaundice. AST and ALT can rise with liver-cell injury, though AST also comes from other tissues. Alkaline phosphatase (ALP) may rise with bile-duct problems or bone activity. Albumin reflects several influences including inflammation, nutrition, protein loss and liver synthetic function.
Abnormal results do not automatically mean liver metastases. Medicines, viral hepatitis, fatty liver, infection and obstruction are among the alternatives. The pattern may affect drug choice or dose and prompt ultrasound or other assessment. Report new jaundice, especially with fever or pain, promptly.
Kidney function and electrolytes
Creatinine is a blood marker used to estimate filtration. eGFR is an estimate of kidney function, interpreted alongside age, muscle mass, trends and acute illness. A “normal” creatinine is not always reassuring in someone with very low muscle mass. Some drug decisions require a specific calculation of creatinine clearance or measured filtration.
Kidney function affects dosing or suitability of selected cancer medicines, hydration plans and contrast decisions. Sodium, potassium and other electrolytes reflect fluid balance and organ function. Report very little urine, marked dehydration, palpitations or severe weakness; do not adjust medicines or fluid intake solely from an online interpretation.
LDH, calcium and clotting tests
LDH is an enzyme released with cell injury or turnover. It may contribute to risk assessment or monitoring in selected lymphomas and germ-cell tumours, but infection, liver problems or a damaged blood sample can also raise it. It cannot diagnose progression on its own.
Calcium can rise because of cancer or other illnesses. Dehydration, constipation, thirst and frequent urination may occur; confusion, severe weakness, vomiting or drowsiness require urgent assessment. Calcium interpretation may need albumin or an ionised calcium measurement. Major sodium, potassium, phosphate or magnesium disturbances can also be serious.
Coagulation tests, such as PT/INR and aPTT, may be requested before selected procedures, with bleeding, liver disease or certain anticoagulant treatments. Not every blood thinner is reliably measured by these tests. Normal results do not eliminate all bleeding risk.
7. Tumour markers: useful only in the right setting
Tumour markers are substances measured in blood or other samples that can help with selected diagnostic, prognostic or monitoring questions. Here we mean circulating markers such as PSA or CA-125; tissue biomarkers are discussed separately. Many markers can rise for non-cancer reasons, and some cancers never produce a measurable rise.
They are not a universal screening panel. The same result means different things before a diagnosis, after surgery or during treatment. Use the appropriate marker for the cancer and interpret its trend with symptoms and imaging.
Sources: [6].
PSA, CA-125, CEA, CA 19-9, AFP, beta-hCG and LDH
| Marker | Selected use | Why the result is not a diagnosis by itself |
|---|---|---|
| PSA | Prostate assessment and monitoring. | Benign enlargement, inflammation and recent procedures can raise it. PSA alone cannot confirm cancer; repeat testing, MRI or biopsy may be appropriate. |
| CA-125 | Assessment and monitoring in selected ovarian cancer settings. | Menstruation, endometriosis, inflammation and fluid in body cavities can raise it. It is not reliable general-population ovarian screening. |
| CEA | Monitoring selected colorectal and other cancers. | Smoking and benign conditions can elevate it; a normal result does not exclude disease. |
| CA 19-9 | Selected pancreatic and biliary cancer assessment/monitoring. | Biliary obstruction or inflammation can raise it substantially; some people cannot produce much CA 19-9. |
| AFP | Selected hepatocellular and non-seminomatous germ-cell tumour settings. | Liver disease and pregnancy can raise it. A normal value does not exclude these cancers. |
| Beta-hCG | Selected germ-cell and gestational trophoblastic disease settings. | Pregnancy and other explanations must be considered; interpretation depends on context. |
| LDH | Part of selected germ-cell and lymphoma risk/monitoring assessments. | Very nonspecific; many kinds of tissue injury can raise it. |
Can normal markers exclude cancer? Does a rise mean failure?
No: normal markers cannot rule out cancer. A marker is often useful for monitoring only when it is informative for that person’s disease. A rising value should prompt review, not a self-directed treatment change.
Doctors consider repeated trends, laboratory methods, treatment timing, symptoms and imaging. For example, CA 19-9 may fall after relief of a blocked bile duct even without cancer treatment. A small fluctuation is different from a sustained rise. Some diseases have specific marker-based decision rules; ask what applies to yours.
8. Molecular testing and precision oncology
Molecular tests look for relevant DNA, RNA or other tumour alterations. A diagnostic biomarker helps identify the disease; a prognostic marker provides information about likely behaviour; a predictive marker helps estimate benefit or resistance to a treatment. A marker can serve more than one role.
This section explains the tests. For the fuller treatment context, read Cancer Biomarkers & Precision Oncology. Testing should be selected for cancer type, stage, available therapies and the question being asked—not ordered solely because a panel is large.
What is next-generation sequencing (NGS)?
NGS reads many genetic regions together. A targeted panel examines a selected set; comprehensive genomic profiling examines a broader range and may assess additional genomic features. DNA testing identifies changes in the genetic code; RNA testing can help identify expressed gene fusions and other alterations. Panel capabilities differ, so “NGS done” does not guarantee every relevant alteration was assessed.
Testing can use suitable tumour tissue or, in selected situations, blood. The laboratory checks sample quality and tumour content; insufficient material can lead to failure or incomplete results. Some clinical questions are answered well by a focused test, IHC or ISH instead.
NGS is especially valuable where multiple results can change systemic treatment. It is not necessary for every patient or every early-stage cancer. Ask about clinical benefit, cost, turnaround, whether the assay covers the needed alteration types and how results will be interpreted.
Common molecular biomarkers: what the names mean
| Biomarker | Patient-friendly explanation |
|---|---|
| EGFR | Selected activating changes can drive some lung cancers and guide matched treatment; different variants behave differently. |
| ALK / ROS1 | Rearrangements can join genes together and drive selected cancers, especially lung cancer. |
| BRAF | A signalling gene; V600 and non-V600 changes are not interchangeable, and treatment depends on tumour type. |
| KRAS | A signalling gene with multiple variants; it may indicate resistance to some treatments or eligibility for selected matched approaches. |
| HER2 / ERBB2 | Mutation, amplification and protein expression are distinct; the relevant test depends on the clinical question. |
| MET | Alterations such as exon 14 skipping or amplification have different meanings and testing requirements. |
| RET / NTRK | Selected fusions, and some RET mutations, may be treatment-relevant. A fusion is not the same as any change in that gene. |
| BRCA1 / BRCA2 | DNA-repair genes; harmful changes can influence selected treatments and sometimes suggest inherited risk. |
| HRD | Homologous recombination deficiency: impaired DNA repair assessed by particular tests; not synonymous with a BRCA mutation or inherited disease. |
| PIK3CA | Selected mutations can guide treatment in certain breast cancer settings. |
| ESR1 | Selected mutations can arise during endocrine treatment and affect subsequent choices in hormone-receptor-positive breast cancer. |
| MSI-H / dMMR | Evidence of an impaired mismatch-repair pathway; can guide selected treatment and hereditary-risk assessment. |
| TMB | Tumour mutational burden estimates mutations per tested DNA amount. Assay, cancer type and treatment setting matter; it is not a universal immunotherapy rule. |
A driver alteration helps a tumour grow or survive; a passenger may not be responsible for its growth. Even a driver does not guarantee that a suitable, accessible drug exists or will work. Drug approvals and access in India must be checked for the exact disease and indication.
Actionable alterations and variants of uncertain significance
- Detected alteration: the laboratory found a change.
- Clinically relevant alteration: evidence links it to diagnosis, prognosis, sensitivity or resistance.
- Approved matched treatment: there is an authorised drug in a defined setting, and the patient must also meet clinical eligibility.
- Trial-relevant alteration: a study may investigate it, but benefit is not established in routine practice.
A variant of uncertain significance (VUS) means there is not enough evidence to classify its importance. A VUS should not automatically select a drug, lead to preventive surgery or trigger predictive testing of relatives. Reclassification may occur over time; the genetics or molecular team can explain follow-up.
“Actionable” in a commercial report can include trials or weak evidence. Ask whether the recommendation is established for your cancer, accessible locally and appropriate at this point in treatment.
Tissue testing versus blood-based testing
| Tissue | Blood-based ctDNA |
|---|---|
| Shows cell appearance and architecture; can establish diagnosis and allow IHC. | Samples DNA released into circulation; may identify alterations when tissue is difficult to obtain. |
| Requires suitable sampling; may represent only one area of the disease. | May reflect more than one tumour deposit, but low shedding can cause false negatives. |
| Old or poorly preserved tissue may be unsuitable; quantity can limit testing. | Some alterations are harder to detect; blood-cell clones can produce misleading findings. |
| Often needed to assess transformation or clarify a new lesion. | Usually cannot establish histology or replace the tissue examination needed for diagnosis. |
Progression, acquired resistance, suspected transformation or inadequate earlier testing may justify repeat molecular assessment. Repeating a panel without a decision it can inform adds expense without guaranteed benefit. A non-informative blood result may need tissue testing.
Sources: [9].
9. Liquid biopsy: what is being sampled?
Liquid biopsy analyses tumour-derived material in a body fluid, usually blood. Circulating tumour DNA (ctDNA) is the fraction of cell-free DNA released by tumour cells; most cell-free DNA in blood is not from cancer. Some liquid-biopsy methods examine circulating tumour cells or other material instead.
A validated assay may identify an actionable alteration or a resistance mechanism in a suitable cancer setting. It may be helpful if a tissue sample is inadequate or difficult to obtain. It is not inherently more accurate or more useful just because it is less invasive.
Sources: [9].
ctDNA: what it can—and cannot—tell us
Selected ctDNA tests can guide targeted treatment, detect resistance alterations or monitor tumour-derived signals. Low-volume disease, some tumour sites and low shedding can result in a negative test despite cancer being present. A blood result with no alteration detected is therefore not the same as “no cancer”.
A positive result also needs interpretation: blood-forming cells can acquire age-related changes, called clonal haematopoiesis, that are not from the tumour. The assay’s purpose matters: a test designed to match drugs is not necessarily validated to detect residual disease or screen healthy people. Tissue remains important for diagnosis and suspected transformation.
Molecular residual disease (MRD)
After treatment intended to eradicate a solid tumour, a sensitive ctDNA test may detect a molecular signal when scans show no disease. This is called molecular residual disease. A positive result can indicate higher recurrence risk, but that does not automatically show which additional treatment improves outcome. A negative result cannot guarantee cure.
In blood cancers, measurable/minimal residual disease testing may use flow cytometry, PCR or sequencing on blood or marrow. Its interpretation and established clinical roles differ from solid-tumour ctDNA testing; results are assay- and disease-specific.
Evidence for ctDNA-guided treatment is evolving and differs by cancer, stage and assay. It is not a routine requirement for every patient. Before paying for a test, ask what a positive or negative result would change, whether that action has supporting evidence and whether a clinical trial is appropriate. Do not stop proven therapy or surveillance solely because ctDNA is negative.
10. Somatic versus germline: is it inherited?
| Somatic | Germline |
|---|---|
| Acquired in tumour cells during a person’s life. | Present from conception in most cells and potentially passed to children. |
| Usually assessed to understand the cancer or select treatment. | Assessed to understand inherited susceptibility and sometimes treatment options. |
| A tumour finding does not automatically mean relatives carry it. | A confirmed harmful variant may support tailored surveillance and family counselling. |
Tumour-only testing cannot always establish whether a finding is inherited. A possible germline result needs an appropriate confirmatory test and counselling. Blood is often used, but the genetics team may select another sample in particular blood-cancer or transplant settings.
Sources: [8].
Germline testing, BRCA and Lynch syndrome
Germline testing looks for inherited cancer predisposition. Genetic counselling explains the potential outcomes, limits, consent, privacy and implications for relatives. A pathogenic or likely pathogenic variant means evidence supports a harmful effect; carrying it does not mean cancer is certain to develop.
BRCA1 and BRCA2 are DNA-repair genes. Harmful inherited variants can increase selected breast, ovarian, pancreatic and prostate cancer risks and may also affect treatment options in an affected person.
Lynch syndrome involves inherited mismatch-repair dysfunction, usually associated with MLH1, MSH2, MSH6, PMS2 or certain EPCAM changes. It increases risks of colorectal, endometrial and other cancers. An abnormal tumour MMR/MSI result prompts assessment but is not itself a germline diagnosis.
Who may need counselling? What does a negative result mean?
Reasons to discuss genetics include cancer at an unusually young age, several related cancers in a family, multiple primary cancers in one person, certain tumour types or a suggestive pathology/molecular result. Some cancer-specific criteria recommend testing even without a strong family history. Not everyone needs the same test.
A negative result means no reportable harmful variant was found within the test’s scope. It may be reassuring when a known familial variant has been excluded, but an “uninformative negative” does not remove all inherited risk. Unknown genes, untested alteration types and non-genetic factors remain. Screening advice still depends on personal and family history; a VUS is not a positive hereditary-cancer diagnosis.
11. Staging: mapping the extent of disease
In TNM systems, T describes the primary tumour’s size and/or local extent, N regional lymph-node involvement, and M distant spread. These are combined into stage groups for many solid cancers. Local disease remains in the starting area; regional disease involves nearby structures or nodes; distant metastases involve remote sites.
Stage I–IV does not apply identically to every cancer. Lymphomas, leukaemias, brain tumours and other diseases may use different classifications. A stage label without the cancer type is incomplete information.
Sources: [15].
Clinical versus pathological stage
cTNM is based on information available clinically, such as examination, imaging and biopsy. pTNM uses surgical pathological assessment where applicable. Following preoperative treatment, a prefix such as yp identifies pathological findings after therapy; it should not simply be treated as an untreated stage.
The original stage and subsequent response or recurrence are recorded separately. More tests may be needed if they clarify resectability, explain a symptom or alter the treatment plan. A patient with an early, low-risk cancer may appropriately need fewer scans than someone with advanced or symptomatic disease.
Does stage IV always mean the same prognosis?
No. Outlook depends on cancer type and biology, where and how extensively it has spread, organ function, general health, treatment options and response. Some cancers remain controllable for long periods; selected metastatic situations can be approached with particularly intensive or potentially curative strategies. Others behave much more aggressively.
A scan alone cannot give a reliable personalised life expectancy. Ask your team about treatment intent, realistic best and typical scenarios, and what the next assessment will clarify. Avoid comparing your prognosis with someone who has a different cancer merely because both are called stage IV.
Sources: [15].
12. How do doctors know treatment is working?
Response assessment combines how you feel, examination, relevant blood tests, imaging and selected tumour markers. After preoperative therapy, the surgical specimen may show pathological response. Molecular tests contribute in defined settings. No single measure tells the full story.
Baseline studies provide a comparison. Follow-up timing depends on the treatment and cancer; scans performed too soon may mislead. Improved symptoms are encouraging but do not alone prove tumour shrinkage. New symptoms should be assessed even if the next routine scan is weeks away.
Sources: [44].
RECIST and the language of response
RECIST means Response Evaluation Criteria in Solid Tumours. It is a standardised way of assessing selected measurable lesions and other disease findings on scans. Specialists compare measurements with the relevant baseline or smallest previous burden; it is more than measuring one lump.
| Term | Meaning |
|---|---|
| Complete response | All disease detectable by the applicable response criteria has disappeared. This is not necessarily permanent cure. |
| Partial response | Enough reduction to meet the relevant shrinkage criteria; some disease remains. |
| Stable disease | Neither enough shrinkage for partial response nor enough worsening for progression. Disease control can be a useful benefit. |
| Progression | Growth, new lesions or other worsening that meets the applicable criteria; treatment and diagnostic reassessment may follow. |
Different diseases and treatment settings use different systems. Lymphoma, myeloma, prostate cancer and brain tumours are not all assessed by ordinary RECIST alone.
Pseudoprogression during immunotherapy
Occasionally, immune-cell infiltration or related changes can make lesions look larger, or reveal apparently new lesions, before subsequent improvement. This is called pseudoprogression. It is uncommon and must not be assumed whenever a scan worsens.
In a clinically stable patient, the team may consider repeat imaging under an appropriate immune-response framework or another investigation. Worsening symptoms, organ compromise or rapid deterioration require prompt review and may indicate true progression. Do not continue or stop treatment on your own while waiting for a confirming scan.
Sources: [45].
PET metabolic response and repeat scans
Metabolic response describes changes in tracer activity; anatomical response describes changes in size or structure. A residual mass may contain scar tissue with little activity, while inflammation may remain active despite tumour control. Interpretation depends on disease-specific criteria, tracer and timing.
Doctors repeat scans to compare disease over time, assess complications, plan local treatment or investigate new symptoms. Frequent scanning without a useful clinical question can cause false alarms, extra procedures, radiation and cost. After progression, a repeat biopsy may assess resistance, transformation or a second diagnosis. See why tissue may be repeated.
13. Preparing safely for tests
Follow the actual instructions from your centre: preparation varies by test, tracer, contrast, sedation and medical conditions. Carry a medicine list, previous reaction details, kidney reports when requested, device information and relevant prior investigations. Do not independently stop anticoagulants, antiplatelets, insulin or other prescribed medicines.
Before a CT scan
- Confirm which area is being scanned and whether intravenous or oral contrast is planned.
- Describe previous contrast reactions precisely; bring any record of the agent and reaction.
- Tell the centre about kidney disease, recent acute kidney injury, diabetes medicines, pregnancy or possible pregnancy.
- Follow the centre’s fasting and hydration instructions; do not force fluids if you have a fluid restriction.
- Ask whether recent creatinine/eGFR is required and whether any medicine needs a clinician-directed adjustment.
Before PET-CT
Preparation depends on the tracer. For FDG PET, the centre generally specifies a fasting period, permitted fluids and avoidance of strenuous exercise beforehand. Blood glucose is checked because glucose and insulin can alter tracer distribution. If you have diabetes, arrange an individual meal/medicine plan in advance; do not omit or add insulin on your own.
Tell the team about pregnancy, breastfeeding, infection, recent vaccination, surgery, chemotherapy, radiotherapy and growth-factor injections. Rest quietly as instructed during tracer uptake. Follow tracer-specific advice afterwards, including any temporary close-contact or breastfeeding precautions. FDG preparation should not automatically be applied to PSMA or DOTATATE scans.
Sources: [7].
Before MRI
Complete the safety questionnaire honestly. Disclose implants, pumps, stimulators, hearing devices, aneurysm clips and metal fragments, even if a previous MRI was uneventful. Remove metal items as directed; bring implant documentation. The MRI team must establish device compatibility.
Mention pregnancy, kidney impairment, previous gadolinium reaction and claustrophobia. Ask in advance about sedation and escort arrangements. Do not enter the magnet area with an unapproved device or oxygen cylinder.
Sources: [27].
Before and after biopsy
Discuss the exact site, technique, anaesthesia, likely information and alternatives during consent. Disclose anticoagulants, antiplatelets, supplements, bleeding history and allergies. The procedural team decides whether blood counts or clotting tests are needed and coordinates any medicine changes with the prescribing clinician.
Ask about fasting, transport and observation time. Before leaving, obtain written wound-care and activity instructions, a contact number and a plan for results. If a blood thinner was interrupted under guidance, clarify exactly when to restart it. Seek help for significant bleeding, increasing swelling, severe pain, breathlessness or fever.
Sources: [2].
Imaging radiation, contrast reactions and kidney safety
X-ray, CT and nuclear medicine use ionising radiation. The aim is the right examination at an appropriate dose when the expected clinical benefit outweighs the risk. Ultrasound and MRI do not use ionising radiation, but they do not answer every question a CT or PET answers. Avoid unnecessary duplicate scans and bring prior images.
Contrast use is individualised. Kidney risk is especially relevant with acute kidney injury or severe impairment; not every person with mild stable kidney disease must avoid contrast. The team may adjust the protocol, choose another modality or arrange precautions. Gadolinium and iodinated contrast are different agents with different considerations.
Tell staff immediately about breathing difficulty, throat tightness, widespread hives or faintness after an injection. Severe reactions need emergency care. Record the actual contrast agent and reaction for future appointments; do not rely only on a vague label such as “dye allergy”.
14. Cancer test myths versus facts
Myth: Biopsy always spreads cancer.
Fact: Clinically meaningful spread is very rare with appropriately planned biopsies; selected procedures need specialist planning. Read why.
Myth: A positive PET always means cancer.
Fact: Infection, inflammation and healing may also take up tracer. Read why.
Myth: A normal PET rules out cancer.
Fact: Small or low-uptake cancers can be missed. Read why.
Myth: A normal CBC means cancer is absent.
Fact: Many solid tumours do not disturb routine blood counts. Read why.
Myth: All cancers raise tumour markers.
Fact: Some never produce an informative blood-marker rise. Read why.
Myth: A rising marker always means treatment failure.
Fact: Trends need clinical interpretation and, where appropriate, imaging or confirmation. Read why.
Myth: Every cancer patient needs NGS.
Fact: The need depends on diagnosis, stage and whether results can inform care. Read why.
Myth: Every mutation has a targeted drug.
Fact: Many alterations have no validated, accessible matched treatment. Read why.
Myth: Liquid biopsy is always better than tissue.
Fact: The two answer different questions; blood testing can miss alterations and usually cannot establish histology. Read why.
Myth: Cancer mutations are always inherited.
Fact: Many are acquired in tumour cells; germline confirmation may be required. Read why.
Myth: More scans always improve outcomes.
Fact: Unnecessary scans can cause false alarms and harm without improving care. Read why.
Myth: MRI is always better than CT.
Fact: The best modality depends on the organ and question. Read why.
Myth: A negative biopsy always rules out cancer.
Fact: Sampling may miss a lesion; a mismatch with other findings needs reassessment. Read why.
Myth: High Ki-67 automatically means stage IV.
Fact: Ki-67 assesses proliferation, not anatomical spread. Read why.
Myth: Stage and grade mean the same thing.
Fact: They describe different aspects of disease. Read why.
15. Frequently asked questions
Why has my doctor advised a biopsy?
To establish what an abnormal area is and obtain information needed for treatment. Read the explanation.
Can biopsy spread cancer?
It does not ordinarily cause clinically meaningful spread. Rare seeding risks are managed by appropriate planning. Read the explanation.
What if the biopsy is inconclusive?
The team may review the sample, perform extra tests or repeat sampling at an informative site. Read the explanation.
What is IHC?
It is tissue staining that detects proteins to help classify a tumour or assess treatment markers. Read the explanation.
Why are additional stains needed?
Cell appearance alone may not distinguish between diagnoses; a panel can clarify the classification. Read the explanation.
What does Ki-67 mean?
It estimates the proportion of tumour cells showing a proliferation marker. Its significance depends on the tumour type. Read the explanation.
What is the difference between grade and stage?
Grade describes microscopic features; stage describes disease extent, with cancer-specific rules. Read the explanation.
Why do I need a CT scan?
It may locate disease, assess spread, measure response or investigate a complication. Ask which question applies. Read the explanation.
Is PET-CT better than CT?
Neither is universally better. PET provides tracer information, while a diagnostic CT provides structural detail. Read the explanation.
Can PET-CT detect every cancer?
No. Small lesions and cancers with low uptake may be missed. Read the explanation.
What does FDG uptake mean?
A glucose-like tracer has accumulated in an area; both cancer and non-cancer tissues can do this. Read the explanation.
What does SUV mean?
It is a semiquantitative tracer measurement, not a standalone cancer diagnosis or stage. Read the explanation.
What are tumour markers?
Substances measured in blood or other samples that help in selected cancer settings. Read the explanation.
Can normal tumour markers rule out cancer?
No. Some cancers produce little or none of the measured marker. Read the explanation.
What is NGS?
Sequencing that examines multiple genetic regions together; test coverage and usefulness vary. Read the explanation.
Does everyone need molecular testing?
No. Selected tests are important for particular diagnoses and treatment decisions. Read the explanation.
What is a driver mutation?
An alteration that contributes to cancer growth or survival. A driver does not always have a proven matched drug. Read the explanation.
What is liquid biopsy?
Testing tumour-derived material in a body fluid, most often blood. Read the explanation.
What is ctDNA?
Circulating tumour DNA: tumour-derived DNA fragments in the bloodstream. Read the explanation.
What is hereditary cancer testing?
Testing for inherited harmful variants that can affect cancer risk and sometimes treatment. Read the explanation.
What is BRCA testing?
Testing BRCA1 and BRCA2. Whether it is tumour or germline testing changes what the result tells you. Read the explanation.
What is MSI-H?
High microsatellite instability, a molecular finding often related to deficient mismatch repair. Read the explanation.
What does PD-L1 mean?
An immune-related protein measured in tissue; the relevant scoring system depends on the treatment setting. Read the explanation.
Why is HER2 tested?
It can help select specific treatments. The cancer type, score and any required confirmation matter. Read the explanation.
Can cancer change after treatment?
Yes. Resistant clones or a different subtype can emerge; selected situations warrant repeat testing. Read the explanation.
Why are scans repeated?
To compare disease, assess treatment or clarify new findings when the result can guide care. Read the explanation.
What does stable disease mean?
There is insufficient change to meet the applicable response or progression criteria; this can represent useful control. Read the explanation.
What is a complete response?
Disease is no longer detectable by the assessment criteria; microscopic disease and future recurrence may still be possible. Read the explanation.
Why might my doctor request a second biopsy?
To obtain adequate tissue, resolve uncertainty, investigate a new lesion or assess resistance or transformation. Read the explanation.
Which test results should I keep?
Keep original reports, addenda, actual scan images, laboratory trends and treatment summaries. Read the explanation.
Does a VUS mean my family is at risk?
A VUS is uncertain and should not be treated as a confirmed inherited harmful variant. Read the explanation.
How long will results take?
The timeline depends on processing and additional tests. Ask for the expected reporting and review plan. Read the explanation.
Can I stop my blood thinner before biopsy?
Only under a coordinated plan from your clinicians; stopping it independently can be dangerous. Read the explanation.
Is a negative ctDNA test proof of cure?
No. A small amount of disease or low shedding may escape detection. Read the explanation.
What should I do if symptoms worsen while waiting?
Contact your team promptly; emergencies must not wait for routine reports. Read the explanation.
16. Questions to ask before a test
- Why is this test necessary?
- What question will it answer?
- Will the result change my treatment or follow-up?
- Is preparation required?
- What are the risks and reasonable alternatives?
- Do any medicines need adjustment under medical guidance?
- When are the report and any additional results expected?
- Who will explain the result and arrange the next step?
- Could further testing be required?
- What is the cost, and is there a clinically equivalent alternative?
Write down the answers and the team’s contact details. If a report arrives before your consultation, note questions rather than making treatment decisions from isolated words.
Understanding and organising your reports
| Folder | What to include |
|---|---|
| Pathology | Final biopsy or surgical reports, specimen site, laboratory details and all addenda; record where blocks and slides are stored. |
| IHC | Marker panel, scores, assay details where reported and any confirmatory ISH. |
| Molecular and genetics | Full reports, sample type/date, test scope, interpretation and counselling notes—not only the first-page summary. |
| Imaging | Reports plus actual images/CDs or secure image access, including baseline and previous comparison scans. |
| Laboratory | Dated results with units and reference ranges; trends for useful markers. |
| Treatment summaries | Operations, drug regimens and dates, radiotherapy details, major complications and current medicines. |
Use a paper file or securely stored digital folder, ordered by date. Share records only through trusted channels; molecular and germline reports contain sensitive personal and family information. A short one-page treatment timeline helps new teams understand the sequence.
An illustrative investigation timeline
- Clinical assessment
Symptoms, history, examination or an abnormal screening result establish the question.
- Initial tests
Targeted blood tests or imaging identify the next useful step.
- Sampling
The safest informative biopsy or cytology method is selected.
- Pathology and selected additional tests
Histology, IHC or molecular studies refine the diagnosis when indicated.
- Staging and team discussion
Relevant scans and clinical information define extent and treatment options.
- Results consultation and plan
Your team explains the findings, remaining uncertainty and treatment or follow-up plan.
This is a sequence, not a promised timetable. Urgent symptoms may accelerate assessment; some tests run in parallel and others depend on earlier results. Contact the team if an expected report or appointment has not arrived.
17. When to seek urgent medical attention
Do not wait for routine test results
- Significant or persistent bleeding after biopsy, fainting or collapse.
- Severe or rapidly increasing pain, swelling or a tense expanding bruise after a procedure.
- New or severe breathlessness, chest pain or coughing significant blood.
- Throat or facial swelling, breathing difficulty, widespread hives with dizziness or suspected severe allergic reaction.
- New weakness, difficulty walking, loss of sensation, seizures, confusion, or new bladder/bowel dysfunction—especially with back pain.
- Rapid clinical deterioration, marked drowsiness, very little urine or inability to keep fluids down.
Seek immediate assessment at the nearest emergency department or call local emergency services. Do not drive yourself if seriously unwell.
Fever after a procedure or signs of serious infection need prompt contact. During chemotherapy or when neutropenia is possible, 38°C (100.4°F) or higher—or your team’s lower threshold—requires immediate advice. Do not wait for “high” fever. Shaking chills or sudden illness can be serious even without fever. If the team cannot be reached promptly, seek emergency care.
Confusion, severe weakness, vomiting or dehydration can reflect serious calcium or other electrolyte disturbances. The symptoms need assessment rather than waiting for the next scheduled blood test.
18. Medical sources and review status
This patient guide draws on the resources below. Disease-specific indications and local availability evolve. The listed source dates are publication dates where specified, not a medical-review date for this chapter.
Medically reviewed and approved by Dr Hakeem Ansar Hussain — Medical Oncologist. Last medically reviewed: . This is educational information, not an individual diagnosis or treatment plan. See Sources & Medical Review and the Medical Disclaimer.
- NCI — How Cancer Is Diagnosed
- ACR/RSNA RadiologyInfo — Biopsy Overview
- American Cancer Society — How Is a Biopsy Done?
- NCI — Surgical Pathology Reports
- NCI — Biomarker Testing for Cancer Treatment
- NCI — Tumor Markers
- ACR/RSNA RadiologyInfo — PET/CT
- NCI — Genetic Testing for Inherited Cancer Risk
- ESMO — ctDNA assay recommendations (2022)
- American Cancer Society — Can Getting a Biopsy Make Cancer Spread?
- Cancer Research UK — Tests for Soft Tissue Sarcoma
- NCI — Liver Cancer Diagnosis
- Cancer Research UK — Blood Tests
- NCI — Cancer Staging
- NCI — Tumor Grade
- NCI — Ki-67 Proliferation Index
- CAP — Immunohistochemistry Topic Center
- CAP/ASCO — HER2 Testing in Breast Cancer, 2023 Update
- CAP — HER2 Testing in Gastroesophageal Adenocarcinoma
- CAP — PD-L1 and TMB Testing in Lung Cancer
- CAP — Gynecologic Biomarker Reporting Protocol
- CAP — MMR and MSI Testing for Immune Checkpoint Inhibitor Therapy
- ACR/RSNA RadiologyInfo — General Ultrasound
- ACR/RSNA RadiologyInfo — Body CT
- ACR/RSNA RadiologyInfo — Contrast Materials
- ACR/RSNA RadiologyInfo — MRI of the Body
- EANM — FDG PET/CT Tumour Imaging Guideline, version 2.0
- ACR/RSNA RadiologyInfo — Prostate MRI and PSMA Imaging Context
- SNMMI/EANM — SSTR PET Imaging of Neuroendocrine Tumours
- ACR/RSNA RadiologyInfo — Mammography
- Cancer Research UK — Tests and Scans
- NCI — Infection and Neutropenia
- Cancer Research UK — Tests for Liver Cancer
- Cancer Research UK — High Calcium in People with Cancer
- NCI — Tumor Marker Tests in Common Use
- Canadian Cancer Society — Tumour Marker Tests
- ESMO — NGS Recommendations for Advanced Cancer (2024)
- AMP/ASCO/CAP — Interpretation and Reporting of Sequence Variants in Cancer
- ESMO — Evolving Clinical Opportunities for ctDNA
- NCI — Measurable Residual Disease
- NCI — BRCA Gene Changes and Genetic Testing
- NCI — RECIST
- NCI — Imaging Response Criteria, including iRECIST
- ACR/RSNA RadiologyInfo — Radiation Dose from X-Ray and CT Exams
Understand your treatment devices
Learn about chemoports, PICC lines and safe vascular access.